| 1 |
NCT02581501 |
Withdrawn |
Prospective Phase I Study of GAX for Metastatic Pancreatic Cancer |
|
- Drug: GAX - Gemcitabine, Abraxane and Xeloda
|
Interventional
|
Phase 1 |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Identification of Maximum Tolerated Dose and Dose Intensity in Patients with Pancreatic Cancer
- Progression Free Survival
|
0 |
All |
18 Years and older (Adult, Older Adult) |
NCT02581501 |
StamfordH |
|
February 2016 |
December 2016 |
December 2016 |
October 21, 2015 |
December 6, 2016 |
|
- Stamford Hospital Bennett Cancer Center
Stamford, Connecticut, United States
|
|
| 2 |
NCT03544255 |
Recruiting
New |
Drug Screening of Pancreatic Cancer Organoids Developed From EUS-FNA Guided Biopsy Tissues |
- Pancreatic Cancer
- Pancreas Adenocarcinoma
|
|
Observational
|
|
- Ying Lv
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Number of organoids successfully generated from pancreatic cancer biopsies
- Response of the pancreatic cancer organoids to the selected anti-cancer drugs
|
50 |
All |
18 Years and older (Adult, Older Adult) |
NCT03544255 |
EFOP-01 |
|
May 1, 2018 |
June 1, 2020 |
September 1, 2020 |
June 1, 2018 |
June 1, 2018 |
|
- Nanjing Drum Tower Hospital the Affiliated Hospital of Nanjing University Medical School
Nanjing, Jiangsu, China
|
|
| 3 |
NCT02934984 |
Recruiting |
Circulating Cell-free Tumor DNA(ctDNA) in Pancreatic Cancer |
|
|
Observational
|
|
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Rates of recurrence in pancreatic cancer patients
- Rates of death in pancreatic cancer patients
|
100 |
All |
20 Years to 90 Years (Adult, Older Adult) |
NCT02934984 |
2016-07-054 |
|
July 2016 |
July 2019 |
January 2020 |
October 17, 2016 |
October 17, 2016 |
|
- Samsung Medical Center
Seoul, Korea, Republic of
|
|
| 4 |
NCT03250078 |
Recruiting |
A Pancreatic Cancer Screening Study in High Risk Individuals Including Those With New-Onset Diabetes Mellitus |
|
- Diagnostic Test: MRI/MRCP
|
Observational
|
|
- Western Connecticut Health Network
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Early Stage Pancreatic Cancer or Precursor Lesions
- Serial Pancreatic MRI Screening
- Serum Bio-bank
|
800 |
All |
50 Years to 80 Years (Adult, Older Adult) |
NCT03250078 |
NH 16-17 |
|
November 2016 |
November 2021 |
November 2023 |
August 15, 2017 |
August 15, 2017 |
|
- Danbury Hospital
Danbury, Connecticut, United States - New Milford Hospital
New Milford, Connecticut, United States - Norwalk Hospital
Norwalk, Connecticut, United States
|
|
| 5 |
NCT02555735 |
Recruiting |
Exceptional Responders With Pancreatic Cancer to Chemotherapy |
|
- Drug: Standard of care chemotherapy
|
Observational
|
|
- Adera Labs, LLC
- Memorial Sloan Kettering Cancer Center
- University of Nebraska
- (and 3 more...)
|
Industry / Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Identify exceptional responders with pancreatic cancer to standard of care chemotherapy
- Correlation of genomic profiles from circulating tumor cells with overall survival
|
30 |
All |
18 Years and older (Adult, Older Adult) |
NCT02555735 |
ADRL-003 |
|
October 2015 |
September 2017 |
September 2018 |
September 22, 2015 |
October 20, 2015 |
|
- Oncology and Hematology Specialists
Denville, New Jersey, United States
|
|
| 6 |
NCT02449967 |
Withdrawn |
HepaSphere Interventional Therapy Using Digital Subtraction Angiography（DSA） for Pancreatic Cancer |
|
- Procedure: interventional therapy
|
Interventional
|
Phase 1
Phase 2 |
- Fuda Cancer Hospital, Guangzhou
- Fuda Cancer Hospital, Guangzhou
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of participants with Adverse events
- Percentage of lesions that show no sign of recurrence 12 months after interventional therapy
- Progress free disease (PFS)
- Overall survival (OS)
|
0 |
All |
18 Years to 80 Years (Adult, Older Adult) |
NCT02449967 |
Pancreatic Cancer HepaSphere |
|
May 2015 |
June 2018 |
June 2020 |
May 21, 2015 |
August 5, 2015 |
|
- Central laboratory in Fuda cancer hospital
Guangzhou, Guangdong, China
|
|
| 7 |
NCT00897832 |
Completed |
Biomarkers in Predicting Response to Treatment in Patients Who Have Undergone Surgery for Pancreatic Cancer |
|
- Other: laboratory biomarker analysis
|
Observational
|
|
- Vanderbilt-Ingram Cancer Center
- National Cancer Institute (NCI)
- Vanderbilt-Ingram Cancer Center
|
Other / NIH |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- Determination if a method of extracting and identifying biomarkers from tissues of the quantity obtained from typical biopsy can be applied in the setting of pancreatic cancer
|
50 |
All |
Child, Adult, Older Adult |
NCT00897832 |
VICC GI 0666
P30CA068485
VU-VICC-GI-0666
VU-VICC-061225 |
|
January 2007 |
December 2007 |
December 2007 |
May 12, 2009 |
March 5, 2013 |
|
- Vanderbilt-Ingram Cancer Center - Cool Springs
Nashville, Tennessee, United States - Vanderbilt-Ingram Cancer Center at Franklin
Nashville, Tennessee, United States - Vanderbilt-Ingram Cancer Center
Nashville, Tennessee, United States
|
|
| 8 |
NCT03513705 |
Not yet recruiting |
Impact of Nationwide Enhanced Implementation of Best Practices in Pancreatic Cancer Care (PACAP-1) |
- Carcinoma, Pancreatic Ductal
|
- Other: Best practices in pancreatic cancer care
|
Interventional
|
Not Applicable |
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
- Dutch Cancer Society
- Netherlands Comprehensive Cancer Organisation (IKNL)
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- 1-year overall survival
- Quality of life
- 3-year overall survival
- (and 5 more...)
|
2142 |
All |
Child, Adult, Older Adult |
NCT03513705 |
W17_454
UVA 2013-5842 |
PACAP-1 |
May 2018 |
June 2020 |
June 2025 |
May 1, 2018 |
May 1, 2018 |
|
|
|
| 9 |
NCT00900003 |
Completed |
Studying Biomarkers in Patients With Pancreatic Cancer |
|
- Genetic: protein analysis
- Other: laboratory biomarker analysis
|
Observational
|
|
- Vanderbilt-Ingram Cancer Center
- National Cancer Institute (NCI)
- Vanderbilt-Ingram Cancer Center
|
Other / NIH |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- Cellular localization of BRCA1 as a predictor of response to cytotoxic agents or radiotherapy
- Correlation of pre-treatment markers with survival and recurrence
- Application of a method of extracting and identifying secreted cytokines and growth factors from biopsy tissue to the pancreatic cancer population
|
53 |
All |
Child, Adult, Older Adult |
NCT00900003 |
VICC GI 0717
P30CA068485
VU-VICC-GI-0717
VU-VICC-070366 |
|
May 2007 |
March 2013 |
March 2013 |
May 12, 2009 |
December 12, 2013 |
|
- Vanderbilt-Ingram Cancer Center - Cool Springs
Nashville, Tennessee, United States - Vanderbilt-Ingram Cancer Center at Franklin
Nashville, Tennessee, United States - Vanderbilt-Ingram Cancer Center
Nashville, Tennessee, United States
|
|
| 10 |
NCT03509298 |
Recruiting |
Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Pancreatic Cancer |
- Advanced Pancreatic Cancer
|
- Biological: Activated CIK and CD3-MUC1 Bispecific Antibody in Treating Pancreatic Cancer
- Procedure: cryotherapy
|
Interventional
|
Phase 2 |
- Fuda Cancer Hospital, Guangzhou
- Benhealth Biopharmaceutical (Shenzhen) Co., Ltd.
- Fuda Cancer Hospital, Guangzhou
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Objective response rate
- Progression-free survival
- Time tumor progression
- (and 3 more...)
|
90 |
All |
18 Years to 75 Years (Adult, Older Adult) |
NCT03509298 |
CD3-MUC1 in pancreatic cancer |
|
April 12, 2018 |
April 12, 2019 |
April 12, 2021 |
April 26, 2018 |
April 26, 2018 |
|
- Institutional Review Board of Guangzhou Fuda Cancer Hospital
Guangzhou, Guangdong, China
|
|
| 11 |
NCT00836407 |
Completed
Has Results |
Ipilimumab +/- Vaccine Therapy in Treating Patients With Locally Advanced, Unresectable or Metastatic Pancreatic Cancer |
|
- Drug: Ipilimumab
- Biological: Pancreatic Cancer Vaccine
|
Interventional
|
Phase 1 |
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Determine if Ipilimumab Alone or in Combination With Pancreatic Tumor Vaccine Has an Acceptable Safety Profile (Less Than 33% Unacceptable Toxicity) in Subjects With Locally Advanced, Unresectable or Metastatic Pancreatic Adenocarcinoma
- Overall Survival (OS)
- To Estimate Overall Response Rate (ORR), Immune Related Best Overall Response Rate (irBOR), Progression Free Survival (PFS), and Duration of Response in Patients Receiving Treatment.
- (and 2 more...)
|
30 |
All |
18 Years and older (Adult, Older Adult) |
NCT00836407 |
J0834
BMS # CA184-081 |
|
February 2009 |
July 2012 |
July 2012 |
February 4, 2009 |
December 10, 2013 |
December 10, 2013 |
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland, United States
|
|
| 12 |
NCT02451982 |
Recruiting |
Neoadjuvant/Adjuvant GVAX Pancreas Vaccine (With CY) With or Without Nivolumab Trial for Surgically Resectable Pancreatic Cancer |
|
- Drug: Cyclophosphamide
- Biological: GVAX pancreatic cancer
- Drug: Nivolumab
|
Interventional
|
Phase 1
Phase 2 |
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Median IL17A expression in vaccine-induced lymphoid aggregates found in surgically resected pancreatic tumors
- Number of participants experiencing immune-related toxicities (IRAEs)
- Overall Survival
- Disease Free Survival
|
50 |
All |
18 Years to 100 Years (Adult, Older Adult) |
NCT02451982 |
J1568
IRB00050517 |
|
February 2016 |
June 2019 |
February 2020 |
May 22, 2015 |
March 14, 2018 |
|
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland, United States
|
|
| 13 |
NCT03460769 |
Recruiting |
Evaluation of a Mixed Meal Test for Diagnosis and Characterization and Type 3c Diabetes Mellitus Secondary to Pancreatic Cancer and Chronic Pancreatitis (DETECT) |
- Pancreatic Cancer
- Chronic Pancreatitis
- Diabetes Mellitus Type 3c
|
- Other: Data Management and Monitoring
|
Observational
|
|
- M.D. Anderson Cancer Center
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- M.D. Anderson Cancer Center
|
Other / NIH |
- Observational Model: Case-Control
- Time Perspective: Prospective
|
- Protocol and Regulatory Compliance Monitoring of Regulatory Documents for Consortium Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer (CPDPC)
|
452 |
All |
40 Years to 84 Years (Adult, Older Adult) |
NCT03460769 |
PA17-0674
1U01DK108328-01 |
|
November 1, 2017 |
November 2020 |
November 2020 |
March 9, 2018 |
March 9, 2018 |
|
- University of Texas MD Anderson Cancer Center
Houston, Texas, United States
|
|
| 14 |
NCT02358161 |
Unknown † |
Phase I/II Study of LDE225 With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer |
|
- Drug: gemcitabine and nab paclitaxel
|
Interventional
|
Phase 1
Phase 2 |
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
- Novartis
- Celgene Corporation
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Dose limiting Toxicity (DLT) and MTD of LDE225 co-administered with gemcitabine and nab-paclitaxel
- Median survival
- Progression free survival
|
56 |
All |
18 Years and older (Adult, Older Adult) |
NCT02358161 |
AMCMEDONC 2013-215
2013-002370-51 |
MATRIX |
September 2013 |
September 2015 |
September 2015 |
February 6, 2015 |
February 6, 2015 |
|
- Academic Medical Center
Amsterdam, Netherlands
|
|
| 15 |
NCT02343835 |
Recruiting |
Anti-Tumor Immunity Induced by IRE of Unresectable Pancreatic Cancer |
|
- Device: NanoKnife LEDC System
|
Interventional
|
Phase 2 |
- Fuda Cancer Hospital, Guangzhou
- Fuda Cancer Hospital, Guangzhou
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Characterization of the intra-tumoral and systemic immune response to IRE in unresectable pancreatic cancers
- Comparison immune response between non-ablated and ablated pancreatic cancer and pre-ablated and post ablated serum
|
20 |
All |
18 Years to 80 Years (Adult, Older Adult) |
NCT02343835 |
JF-20150113(4) |
|
January 2015 |
January 2017 |
January 2020 |
January 22, 2015 |
March 29, 2016 |
|
- FUDA Cancer Hospital
Guangzhou, Guangdong, China
|
|
| 16 |
NCT03398291 |
Not yet recruiting |
Simultaneous Resection of Pancreatic Cancer and Liver Oligometastasis After Induction Chemotherapy |
- Pancreatic Cancer
- Liver Metastases
- Surgery
|
- Procedure: Synchronous resection of primary pancreatic cancer and liver oligometastasis
- Drug: Standard chemotherapy
|
Interventional
|
Phase 3 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Real overall survival
- Overall survival
- Quality of life
- (and 2 more...)
|
300 |
All |
18 Years to 75 Years (Adult, Older Adult) |
NCT03398291 |
CSPAC-1 |
|
June 1, 2018 |
June 1, 2023 |
June 1, 2025 |
January 12, 2018 |
January 16, 2018 |
|
- Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center; Pancreatic Cancer Institute, Fudan University
Shanghai, Shanghai, China
|
|
| 17 |
NCT02162823 |
Completed |
Clinical Trial of Pancreatic Cancer in Stockholm. |
|
- Procedure: Pancreatic Surgery
|
Observational
|
|
- Karolinska University Hospital
|
Other |
- Observational Model: Case-Control
- Time Perspective: Prospective
|
- Survival
- Factors influencing survival
|
600 |
All |
18 Years to 85 Years (Adult, Older Adult) |
NCT02162823 |
2006/1089-31/4 |
SPP |
May 2007 |
February 2017 |
February 2017 |
June 13, 2014 |
August 31, 2017 |
|
- Karolinska University Hospital, Gastrocentrum
Stockholm, Sweden
|
|
| 18 |
NCT01102569 |
Unknown † |
Pancreatic Cancer Genetics |
|
|
Observational
|
|
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Frequency of Three BRCA1/2 Mutations in Ashkenazi Jewish Patients
- Individual Frequency of Three Mutations
- Frequency of disease modifying mutations
|
100 |
All |
18 Years to 85 Years (Adult, Older Adult) |
NCT01102569 |
AAAC6344 |
|
January 2008 |
August 2015 |
August 2016 |
April 13, 2010 |
July 3, 2015 |
|
- Columbia University Medical Center
New York, New York, United States
|
|
| 19 |
NCT01272791 |
Completed |
Trial of Gemcitabine With or Without Bavituximab in Patients With Previously Untreated Stage IV Pancreatic Cancer |
- Metastatic Pancreatic Cancer
|
- Biological: bavituximab
- Drug: Gemcitabine
|
Interventional
|
Phase 2 |
- Peregrine Pharmaceuticals
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall survival of patients with stage IV pancreatic cancer treated with gemcitabine alone or gemcitabine with bavituximab.
- Progression-free survival of patients with stage IV pancreatic cancer treated with gemcitabine alone or gemcitabine with bavituximab.
- Determine overall response rate (ORR)
- (and 3 more...)
|
70 |
All |
18 Years and older (Adult, Older Adult) |
NCT01272791 |
PPHM 1002 |
|
January 2011 |
February 2013 |
March 2013 |
January 10, 2011 |
April 19, 2017 |
|
- Ironwood Cancer & Research Centers
Chandler, Arizona, United States - Moores UCSD Cancer Center
La Jolla, California, United States - Lynn Cancer Institute
Boca Raton, Florida, United States - (and 16 more...)
|
|
| 20 |
NCT00614601 |
Terminated |
Low Dose Vaccine Study for Surgically Resected Pancreatic Cancer |
|
- Biological: HyperAcute(R)-Pancreatic Cancer Vaccine
|
Interventional
|
Phase 2 |
- NewLink Genetics Corporation
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- The primary objective of this Phase II trial is to assess disease-free survival (DFS) at one (1) year following initiation of treatment as the primary endpoint of the study in subjects treated with the HyperAcute®-Pancreatic Cancer Vaccine
- We will use overall survival and adverse events rates as secondary endpoints.
|
9 |
All |
18 Years and older (Adult, Older Adult) |
NCT00614601 |
NLG0305
OBA#0704-844 |
|
January 2008 |
May 2010 |
December 2014 |
February 13, 2008 |
June 26, 2015 |
|
- University of Louisville
Louisville, Kentucky, United States
|
|
| 21 |
NCT00569387 |
Completed |
Vaccine Study for Surgically Resected Pancreatic Cancer |
|
- Biological: HyperAcute(R)-Pancreatic Cancer Vaccine
|
Interventional
|
Phase 2 |
- NewLink Genetics Corporation
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- The primary objective of this Phase II trial is to assess disease-free survival (DFS) at one (1) year following initiation of treatment as the primary endpoint of the study in subjects treated with the HyperAcute®-Pancreatic Cancer Vaccine
- We will use overall survival and adverse events rates as secondary endpoints.
|
73 |
All |
18 Years and older (Adult, Older Adult) |
NCT00569387 |
NLG0205
OBA#0701-829 |
|
December 2007 |
March 2011 |
December 2014 |
December 7, 2007 |
June 26, 2015 |
|
- Mayo Clinic - Scottsdale
Scottsdale, Arizona, United States - University of Southern California
Los Angeles, California, United States - University of California - Irvine
Orange, California, United States - (and 15 more...)
|
|
| 22 |
NCT02079623 |
Unknown † |
Electroporation (NanoKnife) as Treatment for Advanced Pancreatic Cancer |
|
- Procedure: Electroporation/ Nano knife treatment
- Device: NanoKnife
|
Interventional
|
Phase 3 |
- Aalborg Universitetshospital
- Uppsala University Hospital
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Tumor response
- CA-19-9
- Overall survival
|
25 |
All |
18 Years and older (Adult, Older Adult) |
NCT02079623 |
PCaNanoK |
NanoKnife |
November 2013 |
November 2015 |
November 2015 |
March 6, 2014 |
March 6, 2014 |
|
- Surgical Department of Gastroenterology, Aalborg University Hospital
Aalborg, Nothern Jutland, Denmark
|
|
| 23 |
NCT00994721 |
Completed |
A Phase III Study of Pancreatic Cancer |
|
|
Observational
|
|
- National Health Research Institutes, Taiwan
- National Taiwan University Hospital
- Chang Gung Memorial Hospital
- (and 6 more...)
|
Other |
- Observational Model: Case Control
- Time Perspective: Prospective
|
- The primary end-point is recurrence-free survival.
- The secondary end-points are overall survival; local and distant control rate, and the quality of life.
|
147 |
All |
20 Years to 75 Years (Adult, Older Adult) |
NCT00994721 |
T3207 |
|
February 2009 |
January 2016 |
January 2016 |
October 14, 2009 |
May 4, 2016 |
|
- Chang-Gung Memorial Hospital
Taipei, Taiwan - Mackay Memorial Hospital
Taipei, Taiwan - National Taiwan University Hospital
Taipei, Taiwan
|
|
| 24 |
NCT02677038 |
Recruiting |
Olaparib for BRCAness Phenotype in Pancreatic Cancer |
|
|
Interventional
|
Phase 2 |
- M.D. Anderson Cancer Center
- AstraZeneca
- M.D. Anderson Cancer Center
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Objective Tumor Response Rate of Olaparib in Participants with Pancreatic Cancer
- Efficacy of Olaparib in Participants with Pancreatic Cancer
|
24 |
All |
18 Years and older (Adult, Older Adult) |
NCT02677038 |
2015-0503
NCI-2016-00351 |
|
November 11, 2016 |
November 2019 |
November 2020 |
February 9, 2016 |
February 28, 2018 |
|
- University of Texas MD Anderson Cancer Center
Houston, Texas, United States
|
|
| 25 |
NCT02718859 |
Unknown † |
Combination of Irreversible Electroporation and NK Immunotherapy for Advanced Pancreatic Cancer |
|
- Biological: NK cells
- Procedure: irreversible electroporation (IRE )
|
Interventional
|
Phase 1
Phase 2 |
- Fuda Cancer Hospital, Guangzhou
- Shenzhen Hank Bioengineering Institute
- Fuda Cancer Hospital, Guangzhou
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Relief degree
- Progress free survival（PFS）
- Overall survival（OS）
|
60 |
All |
18 Years to 80 Years (Adult, Older Adult) |
NCT02718859 |
NK-pancre |
|
March 2016 |
March 2017 |
March 2017 |
March 24, 2016 |
July 19, 2016 |
|
- Central laboratory in Fuda cancer hospital
Guangzhou, Guangdong, China
|
|
| 26 |
NCT02080221 |
Recruiting |
BrUOG 292: FOLFOX-A For Metastatic Pancreatic Cancer: A Phase II Brown University Oncology Research Group Trial |
- Metastatic Pancreatic Cancer
|
|
Interventional
|
Phase 2 |
- howard safran
- Brown University
- Lifespan
- (and 2 more...)
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Survival for patients with metastatic pancreatic cancer with first-line treatment with FOLFOX-A as compared to historical controls of gemcitabine alone.
- Toxicities associated with FOLFOX-A for metastatic pancreatic cancer
|
50 |
All |
18 Years and older (Adult, Older Adult) |
NCT02080221 |
BrUOG 292 |
|
August 2014 |
September 2018 |
December 2018 |
March 6, 2014 |
December 13, 2017 |
|
- Southcoast centers for cancer care
Fairhaven, Massachusetts, United States - Memorial Hospital of Rhode Island
Pawtucket, Rhode Island, United States - Lifespan Hospitals (The Miriam and RI Hospital, East Greenwich, Newport)
Providence, Rhode Island, United States
|
|
| 27 |
NCT01692873 |
Recruiting |
Prognostic and Predictive Biomarkers of Therapeutic Response in Pancreatic Tumors |
|
- Procedure: suspected pancreatic tumor
|
Interventional
|
Not Applicable |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Other
|
|
300 |
All |
18 Years and older (Adult, Older Adult) |
NCT01692873 |
PACAomics / IPC 2011-004 |
PACAomics |
February 2012 |
December 2017 |
December 2017 |
September 25, 2012 |
June 21, 2017 |
|
- Marine GILABERT, MD
Marseille, France
|
|
| 28 |
NCT00885248 |
Unknown † |
Integrated Positron Emission Tomography - Computed Tomography (PET-CT) in Patients With Pancreatic Cancer |
|
|
Observational
|
|
|
Other |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- Staging of pancreatic cancer
- Diagnosis of pancreatic cancer
|
70 |
All |
18 Years to 75 Years (Adult, Older Adult) |
NCT00885248 |
2008-0623 |
|
January 2009 |
November 2009 |
December 2009 |
April 21, 2009 |
April 21, 2009 |
|
- Asan Medical Center
Seoul, Korea, Republic of
|
|
| 29 |
NCT03001505 |
Withdrawn |
Registry for Pancreatic Cancer |
|
|
Observational
|
|
|
Other |
- Observational Model: Cohort
- Time Perspective: Other
|
- Overall survival
- Disease-free survival
- Metastasis
- Local recurrence
|
0 |
All |
18 Years and older (Adult, Older Adult) |
NCT03001505 |
Pro00075769 |
|
May 4, 2017 |
April 2037 |
April 2037 |
December 23, 2016 |
December 6, 2017 |
|
- Duke University Health System
Durham, North Carolina, United States - Duke University Medical Center
Durham, North Carolina, United States
|
|
| 30 |
NCT02654288 |
Recruiting |
Dynamic Changes of Sera Immunoglobulin G4 and Interleukin-10 in the Patients of Pancreatic Cancer After Chemotherapy |
- Pancreatic Neoplasms
- Inflammation
|
- Other: gemcitabine-based chemotherapy
|
Observational
|
|
- gwcmc
- National Natural Science Foundation of China
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- The dynamic change patterns of sera IgG4 and IL-10 of pancreatic cancer after gemcitabine-based chemotherapy will be recorded.
- The correlation of the changes of IgG4 and IL-10 with the tumor marker during chemotherapy will be analyzed
- The correlation of the changes of IgG4 and IL-10 with the efficacy of chemotherapy evaluated by intravenous enhanced CT during chemotherapy will be analyzed
- The correlation of the changes of IgG4 and IL-10 with the overall survival after chemotherapy will be analyzed.
|
300 |
All |
18 Years to 75 Years (Adult, Older Adult) |
NCT02654288 |
81272573 |
|
January 2016 |
December 2018 |
January 2019 |
January 13, 2016 |
January 26, 2016 |
|
- Department of General Surgery, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Sciences
Beijing, Beijing, China
|
|
| 31 |
NCT02459652 |
Active, not recruiting |
Neoadjuvant S-1 and Concurrent Radiotherapy for Borderline Resectable Pancreatic Cancer |
|
- Drug: S-1
- Radiation: Radiation Therapy
|
Interventional
|
Phase 2 |
- Japan Adjuvant Study Group of Pancreatic Cancer
- Japan Agency for Medical Research and Development
- Pharma Valley Center
- Japan Adjuvant Study Group of Pancreatic Cancer
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- R0 resection rate
- Overall survival
- Disease-free survival
- (and 6 more...)
|
50 |
All |
20 Years to 75 Years (Adult, Older Adult) |
NCT02459652 |
JASPAC 05 |
|
September 2012 |
April 2016 |
September 2018 |
June 2, 2015 |
June 29, 2016 |
|
- Aichi Cancer Center
Nagoya, Aichi, Japan - Nagoya University Hospital
Nagoya, Aichi, Japan - Hirosaki University Hospital
Hirosaki, Aomori, Japan - (and 19 more...)
|
|
| 32 |
NCT02449135 |
Completed |
Nano Drug Interventional Therapy Using Digital Subtraction Angiography（DSA） for Pancreatic Carcinoma |
|
- Procedure: interventional therapy
|
Interventional
|
Phase 1
Phase 2 |
- Fuda Cancer Hospital, Guangzhou
- Fuda Cancer Hospital, Guangzhou
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of participants with Adverse events
- Percentage of lesions that show no sign of recurrence 12 months after interventional therapy
- Progress free disease (PFS)
- Overall survival (OS)
|
60 |
All |
18 Years to 80 Years (Adult, Older Adult) |
NCT02449135 |
Nano drug pancreatic cancer |
|
May 2015 |
February 2016 |
February 2016 |
May 20, 2015 |
February 25, 2016 |
|
- Central laboratory in Fuda cancer hospital
Guangzhou, Guangdong, China
|
|
| 33 |
NCT03417921 |
Not yet recruiting |
A Study of ABTL0812 in Pancreatic Cancer |
|
- Drug: sodium 2-hydroxylinoleic
|
Interventional
|
Phase 1
Phase 2 |
- Ability Pharmaceuticals SL
- The Cleveland Clinic
|
Industry / Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
|
46 |
All |
18 Years and older (Adult, Older Adult) |
NCT03417921 |
ABT-C6-2017 |
Pancreatic |
September 1, 2018 |
September 1, 2020 |
September 2, 2020 |
January 31, 2018 |
January 31, 2018 |
|
|
|
| 34 |
NCT01488552 |
Completed |
Gemcitabine+Nab-paclitaxel and FOLFIRINOX and Molecular Profiling for Patients With Advanced Pancreatic Cancer |
- Stage IV Pancreatic Cancer
|
- Drug: Gemcitabine
- Drug: nab-paclitaxel
- Drug: FOLFIRINOX
- (and 3 more...)
|
Interventional
|
Phase 1
Phase 2 |
- Pancreatic Cancer Research Team
- Pancreatic Cancer Research Team
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Complete Response Rate
- One-Year Survival Endpoint
- Efficacy Endpoints using biomarkers
- Observing toxicity outcomes
|
60 |
All |
18 Years and older (Adult, Older Adult) |
NCT01488552 |
PCRT 11-002 |
|
November 2011 |
August 2015 |
August 2016 |
December 8, 2011 |
August 18, 2016 |
|
- TGen Clinical Research Services (TCRS)
Scottsdale, Arizona, United States - Disney Family Cancer Center
Burbank, California, United States - Virginia Piper Cancer Institute (VPCI)
Minneapolis, Minnesota, United States - (and 2 more...)
|
|
| 35 |
NCT01492907 |
Completed |
Pilot Study of Meat-Borne Carcinogens and Pancreatic Cancer |
|
- Radiation: MeIQx
- Procedure: Pancreatectomy
|
Interventional
|
Phase 1 |
- University of Minnesota - Clinical and Translational Science Institute
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- Pharmacokinetic Metabolite Profile of Radiolabeled MeIQx in Blood
- Pharmacokinetic Metabolite Profile of Radiolabeled MeIQx in Urine
- Quantify [14C]MeIQx-DNA adducts in human pancreas
- Quantify ambient adducts in the human pancreas
|
8 |
All |
18 Years and older (Adult, Older Adult) |
NCT01492907 |
2011NTLS016 |
|
January 2012 |
April 2013 |
April 2013 |
December 15, 2011 |
August 22, 2014 |
|
- Masonic Cancer Center, University of Minnesota
Minneapolis, Minnesota, United States
|
|
| 36 |
NCT02702986 |
Recruiting |
Safety and Feasibility of imILT Locally Advanced Pancreatic Cancer (LAPC) |
|
- Procedure: immunostimulating Interstitial Laser Thermotherapy
- Device: Laser
|
Interventional
|
Phase 1 |
- Universita di Verona
- Clinical Laserthermia Systems AB
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
- The immunostimulating effects of imILT
- Quality of Life after the application of imILT on pancreatic cancer, using European Organisation for Research and Treatment of Cancer Quality of life Questionnaire C30
- (and 3 more...)
|
10 |
All |
18 Years to 85 Years (Adult, Older Adult) |
NCT02702986 |
CTP-2015-001 |
|
February 2016 |
March 2018 |
March 2018 |
March 9, 2016 |
August 24, 2016 |
|
- University of Verona Hospital
Verona, Italy
|
|
| 37 |
NCT01744353 |
Completed
Has Results |
BrUOG 278: FOLFOX-A For Pancreatic Cancer A Brown University Oncology Research Group Study |
- Metastatic Pancreatic Cancer
|
- Drug: Dose level 1
- Drug: Dose level 2/MTD
- Drug: Dose level 3
|
Interventional
|
Phase 1 |
- Brown University
- Lifespan
- Rhode Island Hospital
- Memorial Hospital of Rhode Island
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Assessment of Toxicities to Define MTD of FOLFOX-Abraxane (A) for Newly Diagnosed, Advanced Pancreatic Cancer.
- Response Rate (if Patient's Tumor(s)Are Progressing or Being Controlled) Following Treatment With FOLFOX-A for Patients With Newly Diagnosed, Advanced Pancreatic Cancer.
|
35 |
All |
18 Years and older (Adult, Older Adult) |
NCT01744353 |
BrUOG 278 |
278 |
November 2012 |
September 2014 |
August 2015 |
December 6, 2012 |
April 11, 2016 |
April 11, 2016 |
- Memorial Hospital
Pawtucket, Rhode Island, United States - Rhode Island Hospital (including Newport and East Greenwich locations)
Providence, Rhode Island, United States - The Miriam Hospital
Providence, Rhode Island, United States
|
|
| 38 |
NCT03531125 |
Not yet recruiting |
Gene Expression in Resectable Pancreatic Cancer |
|
- Procedure: Endoscopic Ultrasound
- Procedure: Pancreaticoduodenectomy
|
Observational
|
|
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Comparison of whole transcriptome RNA sequencing of EUS derived pre-operative sample and whole transcriptome RNA sequencing of biopsies taken from the pancreatic cancer during resection
- Percentage and number of patients that undergo EUS and surgery that have a) histopathological evidence of adenocarcinoma in their biopsy and surgical samples, and b) of suitable RNA quality for analysis
|
10 |
All |
18 Years and older (Adult, Older Adult) |
NCT03531125 |
OCTO_087 |
NEOPANC-01 |
June 2018 |
December 2019 |
December 2019 |
May 21, 2018 |
May 28, 2018 |
|
- Oxford University Hospitals NHS Foundation Trust
Oxford, United Kingdom
|
|
| 39 |
NCT03404661 |
Recruiting |
Optical and Biochemical Biomarkers in Early Pancreatic Cancer |
|
- Drug: Synthetic Human Secretin
|
Observational
|
|
|
Other |
- Observational Model: Case-Control
- Time Perspective: Prospective
|
- Methylated DNA markers as measured by mean percentage of total human DNA per pancreatic juice volume
|
100 |
All |
18 Years and older (Adult, Older Adult) |
NCT03404661 |
17-005211 |
|
January 11, 2018 |
December 24, 2018 |
May 24, 2019 |
January 19, 2018 |
January 19, 2018 |
|
- Mayo Clinic in Florida
Jacksonville, Florida, United States
|
|
| 40 |
NCT02637596 |
Completed |
Quality of Life After Radiofrequency Ablation of Pancreatic Cancer |
|
- Procedure: Radiofrequency ablation
|
Interventional
|
Not Applicable |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Quality of life after RFA of pancreatic cancer
- 3- months perioperative morbidity and mortality
|
1 |
All |
18 Years and older (Adult, Older Adult) |
NCT02637596 |
NT 14579-3 |
|
February 2013 |
January 2014 |
December 2015 |
December 22, 2015 |
December 28, 2015 |
|
- Department of surgery Masaryk University Hostpital Brno
Brno, Bohunice, Czech Republic
|
|
| 41 |
NCT03524677 |
Not yet recruiting |
Mutation of K-RAS, CDKN2A, SMAD4 and TP53 in Borderline Resectable Pancreatic Cancer: Role of Liquid Biopsy in Preoperative Diagnosis |
|
- Diagnostic Test: Liquid Biopsy
- Diagnostic Test: Immunohistochemestry
|
Observational
|
|
- University of Roma La Sapienza
- Sant'Andrea University Hospital
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Vascular Invasion
- Overall Survival
- Disease free survival
- N stage
|
108 |
All |
18 Years to 99 Years (Adult, Older Adult) |
NCT03524677 |
17_D'Angelo |
|
June 2018 |
November 2019 |
January 2020 |
May 15, 2018 |
May 15, 2018 |
|
|
|
| 42 |
NCT01104129 |
Active, not recruiting |
Stool Testing for Pancreatic Cancer |
|
|
Observational
|
|
- Columbia University
- Mayo Clinic
|
Other |
- Observational Model: Case-Control
- Time Perspective: Prospective
|
- Positive mutation rate in tumors/IPMN lesions vs. control
- Percentage of patients with genetic abnormalities correctly detected in stool samples
|
158 |
All |
18 Years to 85 Years (Adult, Older Adult) |
NCT01104129 |
AAAD8007 |
|
July 9, 2009 |
July 2019 |
July 2020 |
April 15, 2010 |
February 8, 2018 |
|
- Columbia University Medical Center
New York, New York, United States
|
|
| 43 |
NCT03392571 |
Not yet recruiting |
Phase II Study of NGC-Triple Regimen in Potentially Resectable Pancreatic Cancer Patients |
- Resectable Pancreatic Cancer
|
|
Interventional
|
Phase 2 |
- Pancreatic Cancer Research Team
- Celgene Inc
- Pancreatic Cancer Research Team
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- To evaluate 2 year survival from date of entry into study
- Determine the number and type of treatment-related adverse events as assessed by CTCAE 4.0
- Histological Response to Pre-Operative Therapy
- (and 5 more...)
|
70 |
All |
18 Years to 75 Years (Adult, Older Adult) |
NCT03392571 |
PCRT 17-001 |
|
February 15, 2018 |
December 30, 2020 |
December 30, 2020 |
January 8, 2018 |
January 8, 2018 |
|
|
|
| 44 |
NCT01995240 |
Completed |
Functional Magnetic Resonance Imaging of Pancreatic Cancer: a Feasibility and Reproducibility Study |
|
|
Interventional
|
Not Applicable |
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- Reproducibility of DCE, T2* and DWI MRI in pancreatic cancer.
- Compare in vivo measurements of tumor vascularity, hypoxia and stroma using DCE-MRI, T2* MRI and DWI with immunohistochemically determined markers of vascularity, hypoxia and stroma in pancreatic tumor tissue
- To explore the relation between in vivo measurements of tumor vascularity, hypoxia and stroma using DCE-MRI, T2* MRI and DWI and treatment outcome.
|
23 |
All |
18 Years and older (Adult, Older Adult) |
NCT01995240 |
NL40501.018.12 |
REMP |
April 2013 |
February 2017 |
February 2017 |
November 26, 2013 |
March 20, 2017 |
|
- Academic Medical Center
Amsterdam, Netherlands
|
|
| 45 |
NCT02578732 |
Recruiting |
FOLFOX-A For Locally Advanced Pancreatic Cancer: A Phase II Brown University Oncology Research Group Trial |
- Locally Advanced Pancreatic Cancer
- Pancreatic Cancer
|
|
Interventional
|
Phase 2 |
- howard safran
- Brown University
- Rhode Island Hospital
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Response rate of FOLFOX-A for patients with locally advanced pancreatic cancer.
- Overall survival for patients with locally advanced pancreatic cancer treated with FOLFOX-A
|
60 |
All |
18 Years and older (Adult, Older Adult) |
NCT02578732 |
BrUOG 318 |
|
June 2016 |
January 2020 |
July 2020 |
October 19, 2015 |
February 5, 2018 |
|
- Rhode Island Hospital and The Miriam Hospital
Providence, Rhode Island, United States
|
|
| 46 |
NCT02148549 |
Unknown † |
Neoadjuvant FIRINOX for Borderline Resectable Pancreatic Cancer - a Pilot Study |
|
|
Interventional
|
Phase 1 |
- Wakayama Medical University
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of participants with toxicity of FIRINOX therapy as neoadjuvant chemotherapy for borderline resectable pancreatic cancer.
- The resection rate of FIRINOX therapy as neoadjuvant chemotherapy for borderline resectable pancreatic cancer.
- The R0 resection rate of FIRINOX therapy as neoadjuvant chemotherapy for borderline resectable pancreatic cancer.
- The optimal treatment schedule of FIRINOX therapy as neoadjuvant chemotherapy for borderline resectable pancreatic cancer.
|
10 |
All |
20 Years to 74 Years (Adult, Older Adult) |
NCT02148549 |
FIRINOX
UMIN000013809 |
FIRINOX |
April 2014 |
February 2017 |
February 2017 |
May 28, 2014 |
July 23, 2015 |
|
- Nagoya University
Nagoya, Aichi, Japan - Kobe University
Kobe, Hyogo, Japan - Nara Prefectual Medical University
Kashihara, Nara, Japan - (and 6 more...)
|
|
| 47 |
NCT02050178 |
Completed |
Dose Escalation Study of OMP-54F28 in Combination With Nab-Paclitaxel and Gemcitabine in Patients With Previously Untreated Stage IV Pancreatic Cancer |
- Pancreatic Cancer
- Stage IV Pancreatic Cancer
|
- Drug: OMP-54F28, Nab-Paclitaxel and Gemcitabine
|
Interventional
|
Phase 1 |
- OncoMed Pharmaceuticals, Inc.
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Safety and tolerability of OMP-54F28 in combination with nab-paclitaxel and gemcitabine in patients with previously untreated Stage IV pancreatic cancer
- Pharmacokinetics (PK) of OMP-54F28 when administered in combination with nabpaclitaxel and gemcitabine to patients with previously untreated Stage IV pancreatic cancer
|
26 |
All |
18 Years to 90 Years (Adult, Older Adult) |
NCT02050178 |
54F28-002 |
|
November 2013 |
June 15, 2017 |
June 15, 2017 |
January 30, 2014 |
April 9, 2018 |
|
- USC/Norris Comprehensive Cancer Center
Los Angeles, California, United States - University of Colorado Hospital Anschutz Cancer Pavilion
Aurora, Colorado, United States - Indiana University Simon Cancer Center
Indianapolis, Indiana, United States - (and 2 more...)
|
|
| 48 |
NCT02005315 |
Completed |
A Study of Vantictumab (OMP-18R5) in Combination With Nab-Paclitaxel and Gemcitabine in Previously Untreated Stage IV Pancreatic Cancer |
- Pancreatic Cancer
- Stage IV Pancreatic Cancer
|
- Drug: Vantictumab
- Drug: Nab-Paclitaxel
- Drug: Gemcitabine
|
Interventional
|
Phase 1 |
- OncoMed Pharmaceuticals, Inc.
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Phase 1b: Safety and tolerability of vantictumab in combination with nab-paclitaxel and gemcitabine in patients with previously untreated Stage IV pancreatic cancer
- Pharmacokinetics (PK) of vantictumab when administered in combination with nab-paclitaxel and gemcitabine to patients with previously untreated Stage IV pancreatic cancer
|
30 |
All |
18 Years to 90 Years (Adult, Older Adult) |
NCT02005315 |
18R5-003 |
|
September 2013 |
October 2017 |
November 2017 |
December 9, 2013 |
January 24, 2018 |
|
- USC/Norris Comprehensive Cancer Center
Los Angeles, California, United States - University of Colorado Hospital Anschutz Cancer Pavillion
Aurora, Colorado, United States - Indiana University Simon Cancer Center
Indianapolis, Indiana, United States - (and 2 more...)
|
|
| 49 |
NCT00409292 |
Completed
Has Results |
RAD001 in Previously Treated Patients With Metastatic Pancreatic Cancer |
|
|
Interventional
|
Phase 2 |
- Dana-Farber Cancer Institute
- Massachusetts General Hospital
- Beth Israel Deaconess Medical Center
- (and 2 more...)
|
Other / Industry |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- To Assess Progression-free Survival of RAD001 at Two Months in Patients With Metastatic Pancreatic Cancer Whose Disease Has Progressed on Gemcitabine Chemotherapy.
- To Assess the Safety of RAD001 in Patients With Metastatic Pancreatic Cancer
- to Assess Response Rate Associated With RAD001 in This Patient Population.
- to Assess Overall Survival Associated With RAD001 in This Patient Population.
|
33 |
All |
18 Years and older (Adult, Older Adult) |
NCT00409292 |
06-197 |
|
January 2007 |
January 2009 |
May 2009 |
December 8, 2006 |
August 11, 2014 |
August 11, 2014 |
- Massachusetts General Hospital
Boston, Massachusetts, United States - Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States - Dana-Farber Cancer Institute
Boston, Massachusetts, United States
|
|
| 50 |
NCT02277834 |
Completed |
Characterizing the Pancreatic Cancer Proteome From Pancreatic Juice |
|
|
Observational
|
|
- University of Alabama at Birmingham
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Compare the proteomic signature of pancreatic adenocarcinoma , pancreatic cancer and control participants to the disease process
- Compare the proteomic profile between pancreatic cancer and pancreatitis
|
9 |
All |
19 Years to 90 Years (Adult, Older Adult) |
NCT02277834 |
UAB 1361 |
|
August 2014 |
April 2016 |
April 2016 |
October 29, 2014 |
May 13, 2016 |
|
- University of Alabama at Birmingham
Birmingham, Alabama, United States
|
|
Create an RSS feed from your search for:
Download the search results for: